KOSS (January 25 ,2021)

 

PTE news 01/21/2021

 8:07a ET 1/21/2021 - Benzinga

PolarityTE Announces Completion Of Target Enrollment In Diabetic Foot Ulcer Trial

Mentioned:

PTE

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

Company Expects to Release Topline Data at the Symposium on Advanced Wound Care—Spring 2021

PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 100 subjects in a randomized controlled trial (RCT) evaluating SkinTE® plus standard of care (SOC) versus SOC alone for the treatment of diabetic foot ulcers (DFUs). PolarityTE plans to report topline data via press release and presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2021 to be held May 12-16, 2021, barring any unforeseen scheduling or other disruptions due to COVID-19. Details for the SAWC 2021 Virtual Conference can be found at https://www.sawcspring.com/.

The primary endpoint of this Diabetic Foot Ulcer Trial (NCT03881254) is a comparison of the percent of index ulcers closed at 12 weeks, and additional details regarding the trial can be found at https://clinicaltrials.gov/ct2/show/study/NCT03881254.

David Seaburg, Chief Executive Officer, commented, "The completion of target enrollment for this DFU RCT is an important milestone for PTE and a step toward building what we believe will be additional scientific evidence to support the potential benefits SkinTE may offer patients suffering from debilitating diabetic foot ulcers."

Nik Sopko, MD, PhD, Chief Scientific Officer, commented, "Enrollment completion of this trial in the midst of a global pandemic highlights the tremendous efforts by trial investigators and a dedicated PolarityTE team. We are incredibly grateful to all of the patients who participated in this study and look forward to presenting the results."

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/202101210051

Today gained 01/25/2021

 

In my opinion OGEN stock is a good time to invest because the company immediately began pre clinical work to produce Covid vaccine . Before the stock turning boom let’s get in🤗 

monday big week for coperate earnings

 

The Nasdaq Composite climbed to a closing record Monday amid sharp volatility in technology stocks and a big week for corporate earnings.

The Nasdaq finished higher by 0.7%. The tech-heavy index jumped as much as 1.4% after the opening bell, then turned negative and tumbled to a 1.3% loss before rebounding. It ended last week at record levels.

The Dow Jones Industrial Average dropped 0.1%, while the S&P 500 added 0.4% to close at a record.

A raft of corporate earnings reports in the coming days is expected to show which corporations are thriving and which are struggling amid the Covid-19 pandemic.

More than one-fifth of the broad S&P 500 index and one-third of Dow components are scheduled to release earnings this week. Starbucks, Verizon and Microsoft are slated (cover/ for Tuesday. Other major tech firms are reporting later in the week, including Apple, Tesla and Facebook on Wednesday.

"The way that management will communicate their outlook will be key for markets," said Sophie Chardon, a cross-asset strategist at Lombard Odier. "Investors will have to weigh the possibility of vaccinations with the reality of new lockdowns" and the impact on each company.

Concerns about Covid-19 vaccine supplies have also sent jitters through the markets. Pharmaceutical giant Merck scrapped its plans to develop a Covid-19 vaccine after trials yielded disappointing results, pulling a major player out of the coronavirus vaccine race. Its shares were roughly flat.

Merck's announcement came after AstraZeneca warned on Friday that its vaccine deliveries to the European Union would lag projections.

"The vaccine rollout is not as speedy or smooth as we had hoped in November," said Liz Ann Sonders, chief investment strategist at Charles Schwab.

Stumbles in the vaccination drive and the spread of new coronavirus variants have helped fuel recent gains in tech stocks. The biggest tech companies are seen as benefactors from stay-at-home orders, as firms and households increase their use of digital technology when operating remotely.

"You're getting rotation out of the more cyclical stocks. These big tech stocks are perceived as a bit of a haven trade," said Michael Hewson, chief market analyst at CMC Markets.

Tech shares have also been a favorite of individual investors who have poured into the stock market over the past year, fueling a broad rally and driving wild moves in some stocks.

One of them, GameStop, was up 18% on Monday, paring gains after it more than doubled in value earlier in the day. The videogame retailer has been at the center of a fight between bullish day traders communicating on the internet forum Reddit, and short sellers, who bet heavily against the stock.

Other stocks that have captured the attention of small investors also made big moves on Monday. Retailer Bed Bath & Beyond climbed nearly 5% while movie-theater chain AMC Entertainment jumped more than 25%.

"The newly minted traders are using message boards and causing just really nutty stuff to happen," Ms. Sonders said.

Investors also are monitoring negotiations over President Joe Biden's plan for additional fiscal stimulus to combat fallout from the pandemic. His proposal for a $1.9 trillion spending package is likely to be a major topic of discussion among U.S. lawmakers this week.

Technology and social-media stocks were volatile. Apple was up 2.3%. Data-analytics firm Palantir Technologies advanced 11% ahead of a high-profile demo of its software planned for Tuesday, paring gains after surging as much as 21% earlier.

Meanwhile, Twitter fell 0.4%% and online marketplace Etsy sank 2.1% with both stocks retreating from morning gains.

Energy stocks and financials were among Monday's underperformers. Chevron shares fell 0.9%, while Goldman Sachs dropped 2.2%, weighing on the Dow.

In corporate news, shares of Kimberly Clark rose 3.2% after the maker of Kleenex and Huggies said it expects net sales to rise in 2021, raised its quarterly dividend and unveiled a $5 billion share-buyback program.

Real-estate firm Tishman Speyer's special-purpose acquisition company TS Innovation Acquisitions soared nearly 45% after it said it would merge with Latch, a smart-lock maker, to take the company public.

Overseas, the pan-continental Stoxx Europe 600 fell 0.8%, which analysts attributed to reports that the U.K. and France were heading toward tighter lockdown measures.

In Asia, most major stock benchmarks rose. The Shanghai Composite Index added 0.5% and Hong Kong's Hang Seng Index climbed 2.4%, buoyed by the rally in tech shares.

South Korea's Kospi Index advanced 2.2%. The index's heavyweight Samsung Electronics rose 3% and chip maker SK Hynix rallied over 5%. Both are slated to report earnings this week.

China's most valuable internet company, Tencent Holdings, jumped nearly 11% to a record in Hong Kong trading. Tencent portfolio company Kuaishou Technology, a TikTok-like video-recording app, announced a coming initial public offering that may value it at about $60 billion.

In bond markets, the yield on the benchmark 10-year U.S. Treasury bond edged down to 1.038%, from 1.090% Friday.

Write to Anna Hirtenstein at anna.hirtenstein@wsj.com and Alexander Osipovich at alexander.osipovich@dowjones.com

© 2021 Dow Jones & Company, Inc.

EBR ( Electrobras)

 The 10 analysts offering 12-month price forecasts for Centrais Eletricas Brasileiras SA have  

• a median target of 9.34, with
•  a high estimate of 12.42 and
•  a low estimate of 6.23. The median estimate represents a 
•  
• +88.78% increase from the last price of 4.95.

 

Eletrobras is a major Brazilian electric utilities company. 

The company's headquarters are located in Rio de Janeiro. 

It is Latin America's biggest power utility company, tenth largest in the world, and is also the fourth largest clean energy company in the world.

plan to buy

ID	STOCK	DATE	PRICES	REMARK PLAN TO INVEST	Field1
15	EBR	1/25/2021	$5.04	purchase on 1/25/2021 open at 5$ highest 5.05 (1share )	one month 28.27 % (to 5.0 $) down from 6.88 $

 

HTBX Market study 📚

Heat Biologics Inc (NASDAQ:HTBX)

The 4 analysts offering 12-month price forecasts for Heat Biologics Inc have a median target of 28.50, with a high estimate of 35.00 and a low estimate of 20.00. The median estimate represents a +314.24% increase from the last price of 6.88. 

52 week highest    30.10

52 WEEKS LOW 1.36    

Table4

ID	Field1	PRICES	UP	DOWN	REASON	DATE	TIME	News	type	Field2
15	HTsBX	$7.93				1/25/2021	12:24:00 PM	HTBX WAS UP ON PREMARKET UP TIL 8.25	Immunotherapies Tcell mediated immuine sy

 

 

TOPS (TOP Ships)

  \

Table4

ID	Field1	PRICES	UP	DOWN	REASON	DATE	TIME	News	type
11	TOPS	$1.64				1/22/2021	1:06:00 PM	BUY AT 1.64
12	TOPS	$1.59				1/13/2021	8:21:00 AM	UP SELL AT 1.59
13	TOPS	$1.71	$1.71			1/25/2021	10:51:00 AM	UP FROM 1.64 TO 1.71
14	TOPS	$1.23				12/17/2020	1:27:00 PM	GET IN AT 1.27

Today gain 1/25/2021